Oncolys BioPharma Inc.
Records under this name other than patents Oncolys BioPharma Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to Oncolys BioPharma Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,943,373 | Telomelysin/GFP-expressing recombinant virus Term ended Term ended Nov 24, 2025 · USPTO record | Term ended | Term ended Nov 24, 2025 | USPTO record |
| US 8,163,892 | Oncolytic virus replicating selectively in tumor cells Term ended Term ended Jul 7, 2023 · USPTO record | Term ended | Term ended Jul 7, 2023 | USPTO record |
| US 8,093,368 | DR5 gene promoter and SIAH-1 gene promoter Term ended Term ended Jun 4, 2023 · USPTO record | Term ended | Term ended Jun 4, 2023 | USPTO record |
| US 9,051,288 | Method for producing 4′-ethynyl d4T Lapsed on the fee record Ended Jun 9, 2019 · USPTO record | Lapsed on the fee record | Ended Jun 9, 2019 | USPTO record |
| US 7,038,028 | Gene Encoding Promoter Domain Fo Tumor Supressor Gene P51 and Use Thereof Lapsed on the fee record Ended May 2, 2018 · High confidence | Lapsed on the fee record | Ended May 2, 2018 | High confidence |